Lucie Simonis, Lorenz Balcar, Anna Schedlbauer, Marta Tonon, Nikolaj Torp, Valeria Santori, Katharina Stopfer, Jan Embacher, Christian Sebesta, Leonie Hafner, Benedikt Silvester Hofer, Nina Dominik, Georg Kramer, Paul Thöne, Michael Trauner, Aleksander Krag, Salvatore Piano, Mattias Mandorfer, Thomas Reiberger, Georg Semmler
{"title":"Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation","authors":"Lucie Simonis, Lorenz Balcar, Anna Schedlbauer, Marta Tonon, Nikolaj Torp, Valeria Santori, Katharina Stopfer, Jan Embacher, Christian Sebesta, Leonie Hafner, Benedikt Silvester Hofer, Nina Dominik, Georg Kramer, Paul Thöne, Michael Trauner, Aleksander Krag, Salvatore Piano, Mattias Mandorfer, Thomas Reiberger, Georg Semmler","doi":"10.1111/apt.70302","DOIUrl":null,"url":null,"abstract":"BackgroundA more granular understanding of hepatic decompensation in cirrhosis has led to the classification of acute decompensation (AD) and non‐acute decompensation (NAD). In this study, we assessed differences in the clinical course of AD versus NAD in patients with ascites as the first decompensation event.Methods505 cirrhosis patients with ascites as first decompensation were included in this single‐center longitudinal cohort study and followed until further decompensation, orthotopic liver transplantation (OLT), or death. AD was defined as grade 3 ascites or ascites with spontaneous bacterial peritonitis (SBP) or acute‐kidney injury (AKI), while NAD was defined as grade 2 ascites. Hospitalisation was recorded.ResultsAmong 505 patients, 296 (58.6%) met the criteria for AD, with 216 (73.0%) requiring hospitalisation. NAD occurred in 209 (41.4%), with 107 (51.2%) requiring hospitalisation.During a median 4.4‐year follow‐up, further decompensation occurred in 65.1%, acute‐on‐chronic liver failure (ACLF) in 27.7%, 10.9% underwent OLT, and 51.1% died. Patients with AD had a higher incidence of further decompensation (at 12 months: 19% and 33%) and a higher risk of transplant‐free mortality (subdistribution hazard ratio [SHR]: 1.43 [95% CI: 1.12–1.82], <jats:italic>p</jats:italic> = 0.004) versus NAD.When stratified by hospitalisation, AD was associated with an increased risk of mortality only in cases requiring hospitalisation (SHR for hospitalised AD vs. non‐hospitalised NAD: 1.89, 95% CI: 1.35–2.65, <jats:italic>p</jats:italic> < 0.001).Inflammation (C‐reactive protein) predicted transplant‐free mortality in AD (SHR per log‐change: 1.20 [95% CI: 1.02–1.41], <jats:italic>p</jats:italic> = 0.032) but not NAD.ConclusionsClassifying patients as AD versus NAD identified subgroups with different risks for further decompensation and transplant‐free mortality.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"23 1","pages":""},"PeriodicalIF":6.7000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.70302","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
BackgroundA more granular understanding of hepatic decompensation in cirrhosis has led to the classification of acute decompensation (AD) and non‐acute decompensation (NAD). In this study, we assessed differences in the clinical course of AD versus NAD in patients with ascites as the first decompensation event.Methods505 cirrhosis patients with ascites as first decompensation were included in this single‐center longitudinal cohort study and followed until further decompensation, orthotopic liver transplantation (OLT), or death. AD was defined as grade 3 ascites or ascites with spontaneous bacterial peritonitis (SBP) or acute‐kidney injury (AKI), while NAD was defined as grade 2 ascites. Hospitalisation was recorded.ResultsAmong 505 patients, 296 (58.6%) met the criteria for AD, with 216 (73.0%) requiring hospitalisation. NAD occurred in 209 (41.4%), with 107 (51.2%) requiring hospitalisation.During a median 4.4‐year follow‐up, further decompensation occurred in 65.1%, acute‐on‐chronic liver failure (ACLF) in 27.7%, 10.9% underwent OLT, and 51.1% died. Patients with AD had a higher incidence of further decompensation (at 12 months: 19% and 33%) and a higher risk of transplant‐free mortality (subdistribution hazard ratio [SHR]: 1.43 [95% CI: 1.12–1.82], p = 0.004) versus NAD.When stratified by hospitalisation, AD was associated with an increased risk of mortality only in cases requiring hospitalisation (SHR for hospitalised AD vs. non‐hospitalised NAD: 1.89, 95% CI: 1.35–2.65, p < 0.001).Inflammation (C‐reactive protein) predicted transplant‐free mortality in AD (SHR per log‐change: 1.20 [95% CI: 1.02–1.41], p = 0.032) but not NAD.ConclusionsClassifying patients as AD versus NAD identified subgroups with different risks for further decompensation and transplant‐free mortality.
期刊介绍:
Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.